Bausch (BHC) reported earnings 30 days ago. What's next for the stock?
LAVAL, QC / ACCESS Newswire / May 14, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the election of the 10 directors nominated at its 2025 annual meeting of shareholders ("Annual Meeting") held on May 13, 2025. The detailed results of the vote for the election of directors are set out below: Name For Withheld Broker Non-Votes Thomas J.
BHCs first-quarter 2025 adjusted earnings and revenues miss estimates. Salix performs lower than expected.
![]() BHC 11 Jun 2014 | Other | $0 Per Share |
![]() BHC 5 Jun 2014 | Other | $0 Per Share |
![]() BHC 20 May 2014 | Other | $0 Per Share |
![]() BHC 16 May 2014 | Other | $0 Per Share |
![]() BHC 2 Apr 2014 | Other | $0 Per Share |
30 Jul 2025 (51 Days) Date | | - Cons. EPS | - EPS |
30 Apr 2025 Date | | - Cons. EPS | - EPS |
20 Feb 2025 Date | | - Cons. EPS | - EPS |
31 Oct 2024 Date | | - Cons. EPS | - EPS |
30 Oct 2024 Date | | - Cons. EPS | - EPS |
![]() BHC 11 Jun 2014 | Other | $0 Per Share |
![]() BHC 5 Jun 2014 | Other | $0 Per Share |
![]() BHC 20 May 2014 | Other | $0 Per Share |
![]() BHC 16 May 2014 | Other | $0 Per Share |
![]() BHC 2 Apr 2014 | Other | $0 Per Share |
30 Jul 2025 (51 Days) Date | | - Cons. EPS | - EPS |
30 Apr 2025 Date | | - Cons. EPS | - EPS |
20 Feb 2025 Date | | - Cons. EPS | - EPS |
31 Oct 2024 Date | | - Cons. EPS | - EPS |
30 Oct 2024 Date | | - Cons. EPS | - EPS |
Drug Manufacturers - Specialty & Generic Industry | Healthcare Sector | Mr. Thomas J. Appio CEO | XSTU Exchange | CA0717341071 ISIN |
CA Country | 20,700 Employees | 11 Jun 2014 Last Dividend | 16 Oct 2000 Last Split | - IPO Date |
Bausch Health Companies Inc. is a global player in the specialized pharmaceutical and medical device sector, with operations spanning both the United States and numerous other countries around the world. Its focus areas include gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. Originally known as Valeant Pharmaceuticals International, Inc., the company underwent a name change in July 2018, marking a new chapter in its history. Headquartered in Laval, Canada, the organization functions through five key segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb, each targeting specific market needs.
Bausch Health's diverse portfolio extends across various medical domains, including: